Sulfur Nonionically Bonded Patents (Class 514/562)
-
Patent number: 8575218Abstract: Methods and pharmaceutical formulations for ameliorating heavy metal toxicity and/or oxidative stress are disclosed, comprising administering pharmaceutically effective amounts of ligands according to the present disclosure.Type: GrantFiled: March 7, 2011Date of Patent: November 5, 2013Assignee: The University of Kentucky Research FoundationInventors: Boyd E. Haley, David A. Atwood, Niladri Gupta
-
Patent number: 8569466Abstract: Prodrug compounds which metabolize into 5-ASA or analogs thereof, and taurine or analogs thereof, in the colon site are disclosed. Pharmaceutical compositions including the compounds, and methods of treatment using the compounds, are also disclosed. Such compounds have utility for treating or preventing gastrointestinal disorders, including colon cancer, ulcerative colitis and Crohn's disease.Type: GrantFiled: September 10, 2009Date of Patent: October 29, 2013Inventor: Nnochiri Ekwuribe
-
Patent number: 8563538Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidneyType: GrantFiled: February 28, 2011Date of Patent: October 22, 2013Assignee: Philera New Zealand LimitedInventors: Garth J. S. Cooper, John R. Baker
-
Patent number: 8563612Abstract: The invention relates to an antimicrobial agent where a cysteine compound is covalently bound to a substrate, in particular by binding through an S—S bridge via a spacer molecule to the substrate. The spacer comprises a carbon chain, optionally interrupted by one or more heteroatoms, e.g. O, S, N, P and Si; the chain is optionally substituted with one or more alkyl groups, preferably lower alkyl groups with 1-5 carbon atoms, hydroxyl groups or alkoxy groups. Also, the invention refers to a substrate that is coated with the antimicrobial agent of the invention. The agent has excellent antimicrobial properties and can be used to coat surfaces and substrates of various devices, such as medical devices or devices used in food handling, in order to prevent or inhibit accumulation and/or growth and/or proliferation and/or the viability of microorganisms and/or formation of biofilm.Type: GrantFiled: March 21, 2006Date of Patent: October 22, 2013Assignee: Cytacoat ABInventors: Anders Wirsen, Birgitta Agerberth, Gudmundur Gudmundsson, Jacob Odeberg, Torbjorn Lindberg
-
Publication number: 20130263298Abstract: A transgenic fly whose genome is modified to express enhanced levels of glutamate-cysteine ligase (GCL) gene is provided. The fly displays phenotypes associated with Alzheimer's disease (AD). Further, a method for diagnosing AD is provided, which includes assessing enzymatic activities in mitochondrial enzymes. Glutathione pathway are investigated by creating Alzheimer's model Drosophila with over-expression of the GCLc gene, inducing redox stress through sleep deprivation, and analyzing mitochondrial electron transport chain (ETC) using colorimetric enzymatic assays. For prevention of AD, it is proposed that the epigenetic approaches be used to increase glutathione levels in vivo before the onset of AD. For treatment of AD, it is proposed that the glutathione levels be increased by GCLc modulation.Type: ApplicationFiled: March 27, 2013Publication date: October 3, 2013Applicant: INDIGO CAPITAL GROUP LLCInventors: Lisa P. MICHAELS, Tess P. Michaels
-
Publication number: 20130252890Abstract: The invention relates to selective oestrogen receptor modulators (SERM) and methods of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of bleeding disorders, osteoporosis, endometriosis, myomata, hormone-dependent tumours, for hormone replacement therapy and for contraception.Type: ApplicationFiled: June 21, 2011Publication date: September 26, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Tim Wintermantel, Carsten Möller, Ulrich Bothe, Reinhard Nubbemeyer, Ludwig Zorn, Dirk Kosemund, Antonius Ter Laak, Rolf Bohlmann, Lars Wortmann, Donald Bierer
-
Publication number: 20130245121Abstract: The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of methods, including, for example, reducing deleterious effects of oxidative stress; treating and/or preventing diabetes; and/or increasing GSH levels.Type: ApplicationFiled: December 27, 2012Publication date: September 19, 2013Inventor: Rajagopal V. Sekhar
-
Patent number: 8536216Abstract: Compositions based on amino acids are described, in particular for oral or parenteral use, suitable for treating heart insufficiency. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of theronine and lysine. Other essential amino acids are preferably also provided (in particular methionine, phenylalanine, histidine, triphtophan) as well as non essential amino acids (in particular tyrosine and/or cyst(e)ine—i.e., cystine and cyst(e)ine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid.Type: GrantFiled: January 26, 2011Date of Patent: September 17, 2013Assignee: Professional Dietetics S.R.L.Inventor: Francesco Saverio Dioguardi
-
Publication number: 20130237603Abstract: A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed.Type: ApplicationFiled: March 12, 2013Publication date: September 12, 2013Applicant: CUMBERLAND PHARMACEUTICALS, INC.Inventors: Leo Pavliv, Amy Rock
-
Publication number: 20130237580Abstract: The present invention relates to novel peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: ApplicationFiled: March 7, 2013Publication date: September 12, 2013Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: POTTAYIL GOVINDAN NAIR SASIKUMAR, MURALIDHARA RAMACHANDRA, SEETHARAMAIAH SETTY SUDARSHAN NAREMADDEPALLI
-
Publication number: 20130237577Abstract: Composition comprising leucine, isoleucine, valine, threonine and lysine for use in prophylactic and/or therapeutic treatment of renal disorders in a subject, preferably an elderly subject.Type: ApplicationFiled: January 12, 2011Publication date: September 12, 2013Inventors: Francesco Saverio Dioguardi, Edoardo Carlo Maria Conti, Giovanni Federico Maria Conti, Isabella Arborio Mella
-
Patent number: 8530515Abstract: Methods for treating or preventing an inflammatory response comprising administering an enantiomer or racemic mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or racemic mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.Type: GrantFiled: August 9, 2011Date of Patent: September 10, 2013Inventors: William Brusilow, Paolo Bernardi
-
Patent number: 8524772Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.Type: GrantFiled: May 11, 2009Date of Patent: September 3, 2013Assignee: Tiara Pharmaceuticals, Inc.Inventors: Yadon Arad, Liang C. Dong
-
ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
Publication number: 20130225605Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.Type: ApplicationFiled: April 22, 2013Publication date: August 29, 2013Applicant: SANOFIInventor: SANOFI -
Publication number: 20130225486Abstract: The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the treatment and/or prevention of malnutrition and disorders related thereto. Such a composition may in particular, but not exclusively, be useful for the elderly population.Type: ApplicationFiled: October 19, 2011Publication date: August 29, 2013Inventors: Denis Breuille, Isabelle Papet, Karine Vidal
-
Publication number: 20130225621Abstract: In one aspect, the invention relates to substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs, derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: August 2, 2011Publication date: August 29, 2013Applicants: University of Toronto Mississauga, University of Central Florida Research Foundation, Inc.Inventors: James Turkson, Patrick Gunning
-
Patent number: 8518993Abstract: The invention concerns a food composition, designed to complement animal feed in methionine, said composition having a synergistic bactericidal effect on the bacterial activity of the bowel flora. Said food composition of bioavailable methionine comprises: a) a bioavailable methionine compound and b) at least one essential oil.Type: GrantFiled: September 11, 2006Date of Patent: August 27, 2013Assignee: Adisseo Ireland Ltd.Inventors: Yves Mercier, Pierre-André Geraert
-
Publication number: 20130217652Abstract: The present invention relates to novel thiobenzyl and sulfinylbenzyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: February 20, 2013Publication date: August 22, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130217685Abstract: The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders.Type: ApplicationFiled: January 8, 2013Publication date: August 22, 2013Applicant: UNIVERSITY OF MASSACHUSETTSInventor: University of Massachusetts
-
Publication number: 20130210771Abstract: This invention provides a combination of antagonists of the hedgehog signaling pathway with a BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with protein tyrosine kinases such as, for example, Src, BCR-ABL and c-kit.Type: ApplicationFiled: February 13, 2013Publication date: August 15, 2013Applicant: IRM LLCInventor: Novartis AG
-
Publication number: 20130203727Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).Type: ApplicationFiled: July 1, 2011Publication date: August 8, 2013Applicant: GILEAD SCIENCES, INC.Inventors: Kerim Babaoglu, Elizabeth Bacon, Kyla Bjornson, Hongyan Guo, Randall L. Halcomb, Paul Hrvatin, John O. Link, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Paul Roethle, James Taylor, James D. Trenkle, Randall W. Vivian, Lianhong Xu
-
Publication number: 20130203769Abstract: Methods for targeting adaptive responses to chemotherapy are described. In various embodiments, a method comprises administering at least one compound that inhibits S6K1, mTORC, or upstream or downstream pathway components of S6K1 or mTORC, in association with administration of at least one antagonist of PPAR?, PPAR?, or PGC1?. In various embodiments, the compound that inhibits S6K1, mTORC, or upstream or downstream pathway components of S6K1 or mTORC is rapamycin, everolimus, temsirolimus, or imatinib. The antagonist of PPAR?, PPAR?, or PGC1? can be GW7647, GW6471, GW501516, GSK3787, or GSK0660.Type: ApplicationFiled: February 7, 2013Publication date: August 8, 2013Applicant: UNIVERSITY OF CINCINNATIInventor: UNIVERSITY OF CINCINNATI
-
Patent number: 8501242Abstract: The present invention relates to compounds as novel thymidylate synthase inhibitors, novel strategies to treat or prevent neoplasia in a subject, methods and compositions thereof.Type: GrantFiled: May 29, 2010Date of Patent: August 6, 2013Assignee: University of Florida Research FoundationInventors: David A. Ostrov, Carmen J. Allegra
-
Publication number: 20130190338Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: ApplicationFiled: March 11, 2013Publication date: July 25, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130190370Abstract: The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental.Type: ApplicationFiled: July 27, 2011Publication date: July 25, 2013Applicant: The Trustees of the University of PennsylvaniaInventors: John Q. Trojanowski, Virginia M.Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huryn, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli
-
Patent number: 8487128Abstract: The invention provides compositions comprising sulindac, R-epimer sulindac, S-epimer sulindac, derivatives, metabolites, and structural analogs thereof which protect normal cells against damage caused by solar rays, oxidative damage, environmental factors, diseases and organisms.Type: GrantFiled: May 5, 2008Date of Patent: July 16, 2013Assignee: CHS Pharma, Inc.Inventors: Herbert Weissbach, Nathan Brot
-
Publication number: 20130172418Abstract: The present disclosure relates to a composition for treating anxiety disorder, particularly to a pharmaceutical composition comprising N-acetyl-L-cysteine or its derivatives for treating anxiety disorder such as post traumatic stress disorder or phobia. In accordance with the present disclosure, N-acetyl-L-cysteine can block the renewal of fear memories for a sustained period of time when it was administered during or after an exposure therapy to treat post traumatic stress disorder or phobia.Type: ApplicationFiled: September 6, 2010Publication date: July 4, 2013Inventors: Suk Woo Choi, Suk Won Lee, Jeong Yeon Kim, Beom Jong Song, In Gie Hong, Sung Mo Park, Ji Hye Kim, Jun Uk Lee, Bo Bae An
-
Patent number: 8475775Abstract: The present invention provides new retinoid compounds and uses of the compounds in humans and animals for non-neoplastic dermal or inflammatory conditions or disorders.Type: GrantFiled: August 24, 2012Date of Patent: July 2, 2013Assignee: The UAB Research FoundationInventors: Wayne J. Brouillette, Donald D. Muccio, Venkatram Reddy Atigadda, John M. Ruppert, Susan M. Ruppert
-
Publication number: 20130165516Abstract: This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.Type: ApplicationFiled: February 1, 2013Publication date: June 27, 2013Applicant: CUMBERLAND PHARMACEUTICALS, INC.Inventor: Cumberland Pharmaceuticals, Inc.
-
Publication number: 20130165394Abstract: Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes.Type: ApplicationFiled: February 19, 2013Publication date: June 27, 2013Applicant: Abbott LaboratoriesInventors: Neile K. Edens, Marti S. Bergana, Kati E. Shearer, Terrence B. Mazer, Joseph E. Walton, David R. Wolf
-
Publication number: 20130165515Abstract: Divalent salts of S-allylmercapto-N-acetylcysteine and related compositions are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compositions include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia.Type: ApplicationFiled: December 3, 2012Publication date: June 27, 2013Inventor: David Michael Ott
-
Patent number: 8470884Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.Type: GrantFiled: October 23, 2012Date of Patent: June 25, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Fariborz Firooznia, Tai-An Lin, Sung-Sau So, Achyutharao Sidduri
-
Publication number: 20130158036Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: ApplicationFiled: November 1, 2012Publication date: June 20, 2013Applicant: PANMIRA PHARMACEUTICALS, LLCInventor: PANMIRA PHARMACEUTICALS, LLC
-
Publication number: 20130158021Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: ApplicationFiled: October 26, 2012Publication date: June 20, 2013Applicant: Massachusetts Institute of TechnologyInventor: Massachusetts Institute of Technology
-
Publication number: 20130158112Abstract: A pharmaceutical composition for inhibiting amyloid beta peptide in a subject includes a compound having the formula (I): where M is selected from a substituted or unsubstituted alkyl, halo, alkoxy, aryl, cyclic, or heterocyclic group; p is an integer from 0-3; X1 is a 3-9 atoms in length linker connecting A and B; B is selected from a substituted or unsubstituted aryl, alkoxy or amine group; and a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier.Type: ApplicationFiled: June 20, 2012Publication date: June 20, 2013Inventors: Jonathan D. Smith, Enakshi Chakrabarti, Subrata Ghosh, Marti Sayre, Gregory Tochtrop
-
Publication number: 20130150381Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of dis orders related to aberrant levels of uric acid.Type: ApplicationFiled: June 15, 2011Publication date: June 13, 2013Applicant: ARDEA BIOSCIENCE, INC.Inventors: Samedy Ouk, Jean-Michel Vernier, Esmir Gunic
-
Publication number: 20130150333Abstract: Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor ? (ROR?) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and/or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of ROR? results in stimulation of TH-17 cell function and/or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).Type: ApplicationFiled: February 13, 2013Publication date: June 13, 2013Applicant: ORPHAGEN PHARMACEUTICALSInventor: Orphagen Pharmaceuticals
-
Patent number: 8461204Abstract: Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g.Type: GrantFiled: August 3, 2012Date of Patent: June 11, 2013Assignee: Signum Biosciences, Inc.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen
-
Publication number: 20130142768Abstract: The present invention relates to a method for promoting eye health by administering to a companion animal a composition comprising at least one polyphenol selected from the group consisting of rosemary, rosemary extract, coffeic acid, coffee extract, turmeric extract, cucurmin, blueberry extract, grapeseed extract, rosemarinic acid, tea extract, and mixtures thereof.Type: ApplicationFiled: February 1, 2013Publication date: June 6, 2013Applicant: THE IAMS COMPANYInventor: The IAMS Company
-
Publication number: 20130143967Abstract: S-allylmercapto-N-acetylcysteine and related compounds are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compounds include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia.Type: ApplicationFiled: December 5, 2011Publication date: June 6, 2013Inventor: David M. Ott
-
Patent number: 8455523Abstract: The present invention is directed to a composition and method for the treatment of hyperlipidemias by targeting Microsomal triglyceride transfer protein (MTP). In particular, the present invention is directed to a combination of at least one MTP inhibitor and at least one lipid-lowering agent, both in an amount effective to treat hyperlipidemias.Type: GrantFiled: January 7, 2011Date of Patent: June 4, 2013Assignee: The Research Foundation of State University of New YorkInventors: M. Mahmood Hussain, Jahangir Igbal, Joby Josekutty
-
Publication number: 20130115177Abstract: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditionsType: ApplicationFiled: December 20, 2012Publication date: May 9, 2013Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Joel Gordon, Maxwell Stock, Greg Stock
-
Publication number: 20130116322Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.Type: ApplicationFiled: October 23, 2012Publication date: May 9, 2013Applicant: Hoffmann-La Roche Inc.Inventor: Hoffmann-La Roche Inc.
-
Publication number: 20130116323Abstract: The described invention provides methods for improving or preserving lung function in a patient suffering from a pulmonary disorder comprising an inflammatory component by administering to the patient a pharmaceutical composition comprising a therapeutic amount of N-acetylcysteine, a derivative of N-acetylcysteine, or a pharmaceutically acceptable salt of N-acetylcysteine, wherein the therapeutic amount is effective to improve or preserve the lung function in the patient.Type: ApplicationFiled: November 2, 2012Publication date: May 9, 2013Applicant: The Leland Stanford Junior UniversityInventor: The Leland Stanford Junior University
-
Publication number: 20130108709Abstract: Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression.Type: ApplicationFiled: October 25, 2012Publication date: May 2, 2013Inventors: Garth James Smith Cooper, Anthony Ronald, John Phillips, Nancy Xiuyin Chen, Deming Gong, Maria Jullig, Anthony John, Rodney Hickey, Sarah Glyn-Jones
-
Publication number: 20130102609Abstract: The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin.Type: ApplicationFiled: December 14, 2012Publication date: April 25, 2013Applicant: LIGAND PHARMACEUTICALS INC.Inventor: Ligand Pharmaceuticals Inc.
-
Publication number: 20130102570Abstract: A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes or obesity is provided by a composition comprising the compound represented by general formula (I) as defined, or a salt thereof.Type: ApplicationFiled: September 28, 2012Publication date: April 25, 2013Applicant: AJINOMOTO CO., INC.Inventor: AJINOMOTO CO., INC
-
Publication number: 20130102538Abstract: The present invention relates to a method for treating an individual having Alzheimer's Disease by using pharmacological chaperones that bind presenelin and thereby increase ?-secretase activity.Type: ApplicationFiled: May 4, 2011Publication date: April 25, 2013Applicant: AMICUS THERAPEUTICS, INC.Inventors: Brandon Wustman, Anthony Stevens
-
Publication number: 20130096127Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: November 29, 2012Publication date: April 18, 2013Applicant: NOVARTIS AGInventor: NOVARTIS AG
-
Publication number: 20130085170Abstract: Composition comprising leucine, isoleucine, valine threonine and lysine for treating angiogenic disorders in elderly subjects.Type: ApplicationFiled: June 4, 2009Publication date: April 4, 2013Applicant: PROFESSIONAL DIETETICS S.R.L.Inventors: Franco Conti, Isabella Arborio Mella, Edoardo Carlo Maria Conti, Giovanni Federico Maria Conti, Francesco Saverio Dioguardi